Literature DB >> 7862924

Nicotine may relieve symptoms of Parkinson's disease.

K O Fagerström1, O Pomerleau, B Giordani, F Stelson.   

Abstract

Two elderly patients with Parkinson's disease were treated with nicotine gum and patch. Reliable changes in symptomatology were noted, using a single-subject, placebo-control reversal design. Improvement was associated with active nicotine dosing and involved diminished tremor and disorganized thinking in one patient and diminished bradykinesia and increased energy in the other.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7862924     DOI： 10.1007/bf02244882

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  4 in total

1.  The Treatment of Post-Encephalitig Parkinsonism by Nicotine.

Authors:  H Moll
Journal:  Br Med J       Date:  1926-06-26

Review 2.  Cigarette smoking and Parkinson's disease.

Authors:  J A Baron
Journal:  Neurology       Date:  1986-11       Impact factor: 9.910

3.  Stimulation of nigrostriatal dopamine neurones by nicotine.

Authors:  W Lichtensteiger; F Hefti; D Felix; T Huwyler; E Melamed; M Schlumpf
Journal:  Neuropharmacology       Date:  1982-10       Impact factor: 5.250

4.  Nicotine-induced sensitization to ambulatory stimulant effect produced by daily administration into the ventral tegmental area and the nucleus accumbens in rats.

Authors:  T Kita; M Okamoto; T Nakashima
Journal:  Life Sci       Date:  1992       Impact factor: 5.037
  4 in total
  30 in total

1.  Effects of nicotine chewing gum on a real-life motor task: a kinematic analysis of handwriting movements in smokers and non-smokers.

Authors:  Oliver Tucha; Klaus W Lange
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 3.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

4.  The effects of nicotine on the human electroretinogram.

Authors:  Stefanie B Varghese; Jamie C Reid; E Eugenie Hartmann; Kent T Keyser
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-12-09       Impact factor: 4.799

5.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

Review 6.  The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.

Authors:  A D Lawrence; B J Sahakian
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

7.  Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.

Authors:  Maryka Quik; Li Chen; Neeraja Parameswaran; Xinmin Xie; J William Langston; Sarah E McCallum
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

8.  The effect of nicotine in combination with various dopaminergic drugs on nigrostriatal dopamine in rats.

Authors:  Sanna Janhunen; Paula Mielikäinen; Päivi Paldánius; Raimo K Tuominen; Liisa Ahtee; Seppo Kaakkola
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

9.  Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.

Authors:  M Quik; Y Polonskaya; J M Kulak; J M McIntosh
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

Review 10.  Nicotine and Parkinson's disease: implications for therapy.

Authors:  Maryka Quik; Kathryn O'Leary; Caroline M Tanner
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.